Large-scale Survey of the Impact of Complementary Medicine on Side-effects of Adjuvant Hormone Therapy in Patients with Breast Cancer

被引:0
作者
Beuth, Josef [1 ]
Schneider, Berthold [2 ]
Van Leendert, Rudolf [3 ]
Uhlenbruck, Gerhard [1 ]
机构
[1] Univ Cologne, Inst Naturopathy, Joseph Stelzmann Str 9, D-50931 Cologne, Germany
[2] Hannover Med Sch, Inst Biometr, Hannover, Germany
[3] Med Data Res, Dusseldorf, Germany
来源
IN VIVO | 2016年 / 30卷 / 01期
关键词
Breast cancer; adjuvant hormone therapy; side-effects; complementary medicine; tolerability; TAMOXIFEN; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: The present clinical investigation was performed to confirm the benefit of complementary medicine in patients with breast cancer undergoing adjuvant hormone therapy (HT). Patients and Methods: The patients (n=1561) were treated according to international guidelines. All patients suffered from arthralgia and mucosal dryness induced by the adjuvant HT. In order to reduce the side-effects, the patients were complementarily treated with a combination of sodium selenite, proteolytic plant enzymes (bromelaine and papain) and Lens culinaris lectin. On case report formulas, self assessment arthralgia and mucosal dryness were documented before and four weeks after complementary treatment. Validation was carried-out by scoring from 1 (no side-effects/optimal tolerability) to 6 (extreme side-effects/extremely poor tolerability). A total of 1,165 patients suffering from severe side-effects (symptom scores >3) were enrolled in this investigation. Results: Overall, 62.6% of patients (729 out of 1,165) suffering from severe arthralgia and 71.7% of patients (520 out of 725) with severe mucosal dryness significantly benefited from complementary medicine. Mean scores of symptoms declined from 4.83 before treatment to 3.23 after four weeks of treatment for arthralgia and from 4.72 before treatment to 2.99 after four weeks of treatment for mucosal dryness, the primary aims of the present investigation. The reduction of side-effects of HT was statistically significant (p<0.001) after four weeks. Conclusion: This investigation confirms studies suggesting a benefit of complementary treatment with the combination of sodium selenite, proteolytic enzymes and L. culinaris lectin in patients with breast cancer.
引用
收藏
页码:73 / 75
页数:3
相关论文
共 13 条
  • [1] [Anonymous], SEXUALITY REPROD MEN
  • [2] BEUTH J, 2010, ANTICANCER RES, V5, P1667
  • [3] Beuth J, 2014, IN VIVO, V28, P979
  • [4] Beuth J, 2013, IN VIVO, V27, P869
  • [5] Proteolytic Enzyme Therapy in Evidence-Based Complementary Oncology: Fact or Fiction?
    Beuth, Josef
    [J]. INTEGRATIVE CANCER THERAPIES, 2008, 7 (04) : 311 - 316
  • [6] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092
  • [7] DeVita V., 2011, Cancer: Principles and Practice of Oncology, V9th
  • [8] German Cancer Society, 2012, INT LEITL DIAGN THER
  • [9] Complementary use of antioxidants and micronutrients in oncology
    Groeber, U.
    Muecke, R.
    Adamietz, I. A.
    Holzhauer, P.
    Kisters, K.
    Buentzel, J.
    Micke, O.
    [J]. ONKOLOGE, 2013, 19 (02): : 136 - 143
  • [10] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    Howell, A
    Cuzick, J
    Baum, M
    Buzdar, A
    Dowsett, M
    Forbes, JF
    Hoctin-Boes, G
    Houghton, I
    Locker, GY
    Tobias, JS
    [J]. LANCET, 2005, 365 (9453) : 60 - 62